Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Abiomed Inc's Business Segments
Abiomed Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 266
Regions Reported
2
Abiomed Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Europe11.4%
- Rest of world1.6%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 30 | 11.4% |
| Rest of world | $ 4 | 1.6% |
Revenue by Product & Service Category - FY
- Product95.2%
- Service and Other4.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 253 | 95.2% |
| Service and Other | $ 13 | 4.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Abiomed Inc
Business Description of Abiomed Inc.
Abiomed Inc. is a leading medical device company that specializes in developing and manufacturing innovative products aimed at supporting and enhancing the pumping function of the heart. Founded in 1981 and headquartered in Danvers, Massachusetts, Abiomed has established itself as a pioneer in the field of cardiovascular health, driven by a commitment to improving patient outcomes and reducing healthcare costs. The company operates globally, with additional locations in Germany, Japan, and Switzerland.
The centerpiece of Abiomeds product offerings is the Impella heart pump, a miniature device designed for temporary circulatory support. The Impella is engineered to assist patients with weakened or damaged hearts during high-risk cardiovascular procedures, including heart transplants, angioplasties, and stent placements. It is inserted through a small incision in the groin and threaded up to the heart, providing critical support during surgery. Uniquely, the Impella is the only FDA-approved temporary heart pump available for certain high-risk patients suffering from advanced heart failure or those undergoing complex cardiac interventions.
In addition to the Impella, Abiomed has expanded its portfolio to include other medical devices that meet the evolving needs of healthcare providers and patients. One notable product is the Breethe OXY-1 System, a portable oxygenation and ventilation system that offers vital support for patients experiencing acute respiratory failure. This innovation underscores Abiomeds dedication to addressing critical healthcare challenges across multiple domains of patient care.
To complement its advanced technologies, Abiomed invests in educational and training programs designed to empower healthcare professionals. These initiatives provide clinicians with the necessary knowledge and skills to optimize the use of Abiomeds medical devices, ensuring safe and effective patient care.
The company has demonstrated robust growth, with annual revenue exceeding $800 million as of 2021, and a workforce of more than 1,500 employees. Abiomed is publicly traded on the NASDAQ under the ticker symbol ABMD.
Central to Abiomeds mission is the focus on patient care and innovation. The company remains dedicated to collaborating with healthcare professionals and organizations to enhance the delivery of care and improve overall patient experiences. Abiomeds commitment to research and development is evident in its continuous pursuit of new technologies and solutions that push the boundaries of cardiovascular care. Through this focus on innovation, the company aims to play a crucial role in transforming the landscape of heart care and medical device technology.
Abiomed Inc. is a leading medical device company that specializes in developing and manufacturing innovative products aimed at supporting and enhancing the pumping function of the heart. Founded in 1981 and headquartered in Danvers, Massachusetts, Abiomed has established itself as a pioneer in the field of cardiovascular health, driven by a commitment to improving patient outcomes and reducing healthcare costs. The company operates globally, with additional locations in Germany, Japan, and Switzerland.
The centerpiece of Abiomeds product offerings is the Impella heart pump, a miniature device designed for temporary circulatory support. The Impella is engineered to assist patients with weakened or damaged hearts during high-risk cardiovascular procedures, including heart transplants, angioplasties, and stent placements. It is inserted through a small incision in the groin and threaded up to the heart, providing critical support during surgery. Uniquely, the Impella is the only FDA-approved temporary heart pump available for certain high-risk patients suffering from advanced heart failure or those undergoing complex cardiac interventions.
In addition to the Impella, Abiomed has expanded its portfolio to include other medical devices that meet the evolving needs of healthcare providers and patients. One notable product is the Breethe OXY-1 System, a portable oxygenation and ventilation system that offers vital support for patients experiencing acute respiratory failure. This innovation underscores Abiomeds dedication to addressing critical healthcare challenges across multiple domains of patient care.
To complement its advanced technologies, Abiomed invests in educational and training programs designed to empower healthcare professionals. These initiatives provide clinicians with the necessary knowledge and skills to optimize the use of Abiomeds medical devices, ensuring safe and effective patient care.
The company has demonstrated robust growth, with annual revenue exceeding $800 million as of 2021, and a workforce of more than 1,500 employees. Abiomed is publicly traded on the NASDAQ under the ticker symbol ABMD.
Central to Abiomeds mission is the focus on patient care and innovation. The company remains dedicated to collaborating with healthcare professionals and organizations to enhance the delivery of care and improve overall patient experiences. Abiomeds commitment to research and development is evident in its continuous pursuit of new technologies and solutions that push the boundaries of cardiovascular care. Through this focus on innovation, the company aims to play a crucial role in transforming the landscape of heart care and medical device technology.
Abiomed Inc. is a distinguished entity in the medical device industry, known for its pioneering solutions in mechanical circulatory support and heart function replacement. The organization focuses on enhancing patient outcomes in cardiac care and respiratory support, exemplifying a strong commitment to innovation and excellence.
Segments
1. Cardiology
The cardiology segment is a core area for Abiomed, where the company develops devices that address a spectrum of heart conditions, including acute myocardial infarction (heart attack), heart failure, and cardiogenic shock. Abiomeds solutions in this sector optimize cardiac output, significantly relieving the strain on the heart and improving survival rates for patients in critical conditions. These devices are essential for emergency interventions, providing immediate support, and also for ongoing treatment strategies to support heart recovery.
Electrophysiology
In the electrophysiology sphere, Abiomed concentrates on developing technologies that assist in diagnosing and managing cardiac arrhythmias, including conditions such as atrial fibrillation and ventricular tachycardia. The devices designed by Abiomed serve to monitor patients effectively and empower cardiologists to implement timely interventions, thus improving both quality of life and clinical outcomes in rhythm management.
Products
1. Impella Heart Pumps
The Impella heart pumps stand as Abiomeds hallmark products, representing a revolutionary advancement in heart support technology. These small, robust pumps are designed for minimally invasive insertion through the femoral artery, providing continuous flow support directly to the heart. The Impella family comprises several models tailored for specific clinical needs, each capable of supporting patients for prolonged periods, ranging from days to weeks. This allows for heart recovery following serious cardiac events. Noteworthy features include real-time hemodynamic monitoring, providing critical data for clinicians to optimize patient care.
Breethe Lung Assist Device
The Breethe lung assist device is a significant enhancement to Abiomed’s product lineup, aimed at patients experiencing acute respiratory failure. It operates as a portable extracorporeal blood oxygenation system, improving oxygen delivery and facilitating the expulsion of carbon dioxide, thus offering robust support for patients respiratory needs during emergencies. Its compact and adaptable design enables use in various healthcare settings, from emergency rooms to specialized care facilities, ensuring patients receive uninterrupted respiratory assistance.
Symphony System
The Symphony system represents an advanced platform dedicated to the integration and management of data from Abiomeds devices, primarily focusing on the Impella heart pumps. This platform is pivotal for healthcare practitioners as it delivers a comprehensive overview of patient data, streamlining coordinated care. The Symphony system plays a crucial role in enhancing clinical decision-making through the provision of real-time data analytics, which is invaluable in managing cases requiring mechanical circulatory support.
Services
1. Customer Support and Training
Abiomed places a high priority on customer support and comprehensive training for healthcare providers. The company offers a dedicated support team that assists healthcare professionals in the optimal use of its products, thereby improving patient care outcomes. Abiomeds thorough training programs cover device operation and maintenance, in addition to best practice guidelines, fostering an environment that prioritizes patient safety and care quality.
Clinical Research and Education
Clinical research is a cornerstone of Abiomed’s strategy to ensure the safety and performance of its product line. The company actively engages in rigorous clinical studies to validate the efficacy of its devices while continually collecting data on their real-world impact. Additionally, Abiomed is committed to educational outreach, raising awareness among healthcare providers about its innovations and the medical conditions they address, thus promoting evidence-based practices and ongoing education within the medical community.
Patient Support
In its dedication to patient care, Abiomed offers robust support systems for patients and their families. This includes comprehensive resources regarding the use of its devices and treatment options. Furthermore, Abiomeds patient advocacy initiatives aim to increase awareness about heart health, emphasizing the significance of mechanical circulatory support. This empowers patients by equipping them with valuable information and resources to make informed healthcare decisions.
Conclusion
In summary, Abiomed Inc. is at the forefront of transforming cardiac and respiratory care through its innovative products and dedicated services. The companys extensive portfolio not only addresses critical healthcare challenges but also supports healthcare professionals in delivering superior patient care, significantly impacting lives across various clinical settings.
Segments
1. Cardiology
The cardiology segment is a core area for Abiomed, where the company develops devices that address a spectrum of heart conditions, including acute myocardial infarction (heart attack), heart failure, and cardiogenic shock. Abiomeds solutions in this sector optimize cardiac output, significantly relieving the strain on the heart and improving survival rates for patients in critical conditions. These devices are essential for emergency interventions, providing immediate support, and also for ongoing treatment strategies to support heart recovery.
Electrophysiology
In the electrophysiology sphere, Abiomed concentrates on developing technologies that assist in diagnosing and managing cardiac arrhythmias, including conditions such as atrial fibrillation and ventricular tachycardia. The devices designed by Abiomed serve to monitor patients effectively and empower cardiologists to implement timely interventions, thus improving both quality of life and clinical outcomes in rhythm management.
Products
1. Impella Heart Pumps
The Impella heart pumps stand as Abiomeds hallmark products, representing a revolutionary advancement in heart support technology. These small, robust pumps are designed for minimally invasive insertion through the femoral artery, providing continuous flow support directly to the heart. The Impella family comprises several models tailored for specific clinical needs, each capable of supporting patients for prolonged periods, ranging from days to weeks. This allows for heart recovery following serious cardiac events. Noteworthy features include real-time hemodynamic monitoring, providing critical data for clinicians to optimize patient care.
Breethe Lung Assist Device
The Breethe lung assist device is a significant enhancement to Abiomed’s product lineup, aimed at patients experiencing acute respiratory failure. It operates as a portable extracorporeal blood oxygenation system, improving oxygen delivery and facilitating the expulsion of carbon dioxide, thus offering robust support for patients respiratory needs during emergencies. Its compact and adaptable design enables use in various healthcare settings, from emergency rooms to specialized care facilities, ensuring patients receive uninterrupted respiratory assistance.
Symphony System
The Symphony system represents an advanced platform dedicated to the integration and management of data from Abiomeds devices, primarily focusing on the Impella heart pumps. This platform is pivotal for healthcare practitioners as it delivers a comprehensive overview of patient data, streamlining coordinated care. The Symphony system plays a crucial role in enhancing clinical decision-making through the provision of real-time data analytics, which is invaluable in managing cases requiring mechanical circulatory support.
Services
1. Customer Support and Training
Abiomed places a high priority on customer support and comprehensive training for healthcare providers. The company offers a dedicated support team that assists healthcare professionals in the optimal use of its products, thereby improving patient care outcomes. Abiomeds thorough training programs cover device operation and maintenance, in addition to best practice guidelines, fostering an environment that prioritizes patient safety and care quality.
Clinical Research and Education
Clinical research is a cornerstone of Abiomed’s strategy to ensure the safety and performance of its product line. The company actively engages in rigorous clinical studies to validate the efficacy of its devices while continually collecting data on their real-world impact. Additionally, Abiomed is committed to educational outreach, raising awareness among healthcare providers about its innovations and the medical conditions they address, thus promoting evidence-based practices and ongoing education within the medical community.
Patient Support
In its dedication to patient care, Abiomed offers robust support systems for patients and their families. This includes comprehensive resources regarding the use of its devices and treatment options. Furthermore, Abiomeds patient advocacy initiatives aim to increase awareness about heart health, emphasizing the significance of mechanical circulatory support. This empowers patients by equipping them with valuable information and resources to make informed healthcare decisions.
Conclusion
In summary, Abiomed Inc. is at the forefront of transforming cardiac and respiratory care through its innovative products and dedicated services. The companys extensive portfolio not only addresses critical healthcare challenges but also supports healthcare professionals in delivering superior patient care, significantly impacting lives across various clinical settings.